DAVENPORT & Co LLC Cuts Stock Position in Novo Nordisk A/S $NVO

DAVENPORT & Co LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 16.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,206,819 shares of the company’s stock after selling 435,679 shares during the period. DAVENPORT & Co LLC’s holdings in Novo Nordisk A/S were worth $112,530,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in NVO. True Wealth Design LLC boosted its holdings in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares in the last quarter. Guerra Advisors Inc bought a new position in Novo Nordisk A/S in the 3rd quarter valued at approximately $25,000. Strengthening Families & Communities LLC purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $30,000. Allianz SE boosted its stake in Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after purchasing an additional 238 shares during the last quarter. Finally, Financial Life Planners bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $33,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo advanced its partnered oral obesity program by starting a Phase I study of LX9851 (licensed from Lexicon), expanding its non?incretin pipeline and preserving upside beyond semaglutide-class drugs. The deal also contains near?term milestone payments and downstream royalties, which de?risks incremental pipeline value. LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
• Positive Sentiment: The FDA cleared a higher dose formulation of Wegovy (Wegovy HD), widening the label and potentially increasing per?patient efficacy and lifetime value for the GLP?1 franchise — a near?term catalyst for revenue growth and market share. FDA clears higher dose of Wegovy as Novo Nordisk ramps up $4B North Carolina expansion
• Positive Sentiment: Management is executing a share repurchase program (part of a DKK15bn 12?month plan), which supports EPS and signals capital allocation discipline. Buybacks can be a floor for the stock amid near?term revenue uncertainty. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Novo’s renewed distribution partnerships (e.g., with telehealth platforms) broaden patient access and may accelerate prescriptions but also shift the margin mix and channel dynamics; watch execution and pricing terms. Seeking Alpha coverage on channel deals
• Negative Sentiment: Analyst Jefferies trimmed its price target and kept a Hold rating, flagging mounting GLP?1 pricing erosion, uncertainty around the oral Wegovy launch trajectory and risk of cannibalization across the portfolio — a driver of near?term downward pressure on sentiment. Jefferies trims Novo Nordisk target
• Negative Sentiment: Semaglutide patent loss in India triggered a flood of very low?price generics (Ozempic/Wegovy copies), sharply undercutting prices there and highlighting how regional patent expiries and low?cost competition can erode pricing and set precedent for other markets. This increases medium?term pricing risk globally. Indian generics flood market for Ozempic/Wegovy

Novo Nordisk A/S Price Performance

NYSE NVO opened at $36.90 on Wednesday. The business’s fifty day moving average price is $47.31 and its 200-day moving average price is $50.81. The stock has a market capitalization of $164.75 billion, a price-to-earnings ratio of 10.63 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. Novo Nordisk A/S has a 1-year low of $35.85 and a 1-year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. CICC Research started coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.